Saturn V Capital Management
Latest statistics and disclosures from Saturn V Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are CRNX, ARGX, CYTK, KALV, MRUS, and represent 43.81% of Saturn V Capital Management's stock portfolio.
- Added to shares of these 10 stocks: ARGX (+$22M), IRON (+$16M), MRUS (+$15M), PCVX (+$13M), FOLD (+$11M), ABVX (+$8.9M), IRWD (+$8.2M), PHAT (+$5.3M), APLS, GERN.
- Started 9 new stock positions in PCVX, IRWD, ABVX, APLS, GERN, PHAT, FOLD, IRON, CABA.
- Reduced shares in these 10 stocks: CRNX (-$22M), Cymabay Therapeutics (-$17M), , CYTK (-$16M), AMLX (-$16M), SRPT (-$14M), Horizon Therapeutics (-$13M), SNDX (-$9.8M), ATXS (-$9.1M), ITOS (-$8.3M).
- Sold out of its positions in AMLX, ATXS, BCRX, BIIB, Cymabay Therapeutics, Jasper Therapeutics, SRPT, Horizon Therapeutics.
- Saturn V Capital Management was a net seller of stock by $-48M.
- Saturn V Capital Management has $249M in assets under management (AUM), dropping by 4.39%.
- Central Index Key (CIK): 0001964437
Tip: Access up to 7 years of quarterly data
Positions held by Saturn V Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Saturn V Capital Management
Saturn V Capital Management holds 21 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Crinetics Pharmaceuticals In (CRNX) | 12.4 | $31M | -41% | 660k | 46.81 |
|
| Argenx Se Sponsored Adr (ARGX) | 10.4 | $26M | +551% | 66k | 393.72 |
|
| Cytokinetics Com New (CYTK) | 7.4 | $19M | -46% | 264k | 70.11 |
|
| Kalvista Pharmaceuticals (KALV) | 6.9 | $17M | -20% | 1.4M | 11.86 |
|
| Merus N V (MRUS) | 6.8 | $17M | +840% | 377k | 45.03 |
|
| Disc Medicine (IRON) | 6.4 | $16M | NEW | 255k | 62.26 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 6.3 | $16M | -8% | 103k | 151.17 |
|
| Anaptysbio Inc Common (ANAB) | 5.3 | $13M | 586k | 22.52 |
|
|
| Vaxcyte (PCVX) | 5.1 | $13M | NEW | 185k | 68.31 |
|
| Cogent Biosciences (COGT) | 4.3 | $11M | -10% | 1.6M | 6.72 |
|
| Amicus Therapeutics (FOLD) | 4.2 | $11M | NEW | 898k | 11.78 |
|
| BioMarin Pharmaceutical (BMRN) | 4.2 | $10M | +8% | 119k | 87.34 |
|
| Syndax Pharmaceuticals (SNDX) | 3.8 | $9.5M | -50% | 398k | 23.80 |
|
| Abivax Sa Sponsored Ads (ABVX) | 3.6 | $8.9M | NEW | 623k | 14.30 |
|
| Ironwood Pharmaceuticals Com Cl A (IRWD) | 3.3 | $8.2M | NEW | 945k | 8.71 |
|
| Phathom Pharmaceuticals (PHAT) | 2.1 | $5.3M | NEW | 501k | 10.62 |
|
| Iteos Therapeutics (ITOS) | 2.1 | $5.3M | -61% | 387k | 13.64 |
|
| Apellis Pharmaceuticals (APLS) | 1.7 | $4.2M | NEW | 72k | 58.78 |
|
| Geron Corporation (GERN) | 1.5 | $3.7M | NEW | 1.1M | 3.30 |
|
| Morphic Hldg (MORF) | 1.2 | $3.0M | -37% | 86k | 35.20 |
|
| Cabaletta Bio (CABA) | 1.2 | $3.0M | NEW | 173k | 17.06 |
|
Past Filings by Saturn V Capital Management
SEC 13F filings are viewable for Saturn V Capital Management going back to 2022
- Saturn V Capital Management 2024 Q1 filed May 15, 2024
- Saturn V Capital Management 2023 Q3 filed Nov. 14, 2023
- Saturn V Capital Management 2023 Q2 filed Aug. 14, 2023
- Saturn V Capital Management 2023 Q1 filed May 15, 2023
- Saturn V Capital Management 2022 Q4 filed Feb. 9, 2023